Darovasertib

Phase 3Small molecule

IIDEAYA Biosciences

Darovasertib is one of 28 small molecule programs targeting Ocular Melanoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ocular MelanomaActive, not recruiting

Uveal MelanomaRecruiting

Ocular MelanomaPhase 2

Active, not recruiting

Uveal MelanomaPhase 3

Recruiting

Competition

Competitive Landscape

29 competitors in Uveal Melanoma

#DrugCompanyPhaseTrials

Afinitor

Yervoy

12 3

Opdivo

Bristol-Myers Squibb

Phase 3

9 4

Alkeran

AApotex Inc.

Approved

1 5

Signifor

RRECORDATI GROUP

Approved

—6

Xalkori

PPrism Pharmaceuticals

Phase 3

3 7

KIMMTRAK

IImmunocore Ltd

Phase 3

5 8

Mekinist

Novartis

Phase 2

2 9

Sutent

Pfizer

Phase 2

2 10

Mektovi

Pfizer

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2030

Phase 2Active, not recruiting

Ocular Melanoma

NCT05907954

Q1 2031

Phase 3Recruiting

Uveal Melanoma

NCT07015190

Q2 2034

Phase 3Recruiting

Uveal Melanoma

NCT07804186

Clinical

Trials by Indication[1]

Ocular Melanoma2 trials

(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma

Active, not recruiting·IIDEAYA Biosciences·Phase 2·NCT05907954·160 enrolled

Neoadjuvant/Adjuvant Trial of Darovasertib in Ocular Melanoma

Active, not recruiting·SSt Vincent's Hospital, Sydney·Phase 2·NCT05187884·15 enrolled

Uveal Melanoma2 trials

Neoadjuvant Darovasertib in Primary Uveal Melanoma

Recruiting·IIDEAYA Biosciences·Phase 3·NCT07015190·520 enrolled

A Randomized, Phase 3, Open-label Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma

Recruiting·IIDEAYA Biosciences·Phase 3·NCT07804186·450 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Darovasertib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Darovasertib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Darovasertib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — IDEAYA Biosciences company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: IIDEAYA Biosciences

Darovasertib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2030

Q1 2031

Q2 2034

Trials by Indication[1]

Ocular Melanoma2 trials

Uveal Melanoma2 trials

References

Drug Info

Quick Facts

Related News